Novo Nordisk

Novo opts to build US API capacity for semaglutide rather than outsource

To supply the Dane: Novo expects First API batch in 2020

By Gareth Macdonald

Novo Nordisk has confirmed it will build an API plant in the US, telling this publication a desire to have manufacturing capacity in the key market for its oral diabetes candidate, semaglutide, drove the decision.